Clinical Trials · NCT04578496
A Safety Extension Study in Patients With Erythropoietic Protoporphyria (EPP)
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Clinuvel Pharmaceuticals Limited
- Enrollment
- 16
- Start date
- Jul 2011
- Locations
- See registry
- Primary endpoint
- Change in Quality of Life Measured Using the EPP-quality of Life Questionnaire (EPP-QoL).